Article Text
Statistics from Altmetric.com
Review of: Keenan JD, Arzika AM, Maliki R, et al. Longer-term assessment of azithromycin for reducing childhood mortality in Africa. N Engl J Med. 2019;380:2207–14.
Study design: This study, MORDOR II, is a continuation study of the MORDOR I trial. In MORDOR I, participants were randomised to receive either azithromycin or placebo biannually for 2 years. MORDOR II is an observational study specifically investigating the effect of subsequent administration of azithromycin to both the original placebo and azithromycin treatment arms of the trial in Niger for a further year. Therefore, participants were followed up for a total of 3 years. Participants and observers in this continuation study remained blinded to their original treatment arm from MORDOR I.
Patients: Infants and children (1–59 months of age) originally enrolled in MORDOR I in Niger, who had previously been randomised to receive either azithromycin or …
Footnotes
Contributors The abstract and commentary were written by both SM and MSD.
Provenance and peer review Not commissioned; internally peer reviewed.